Health Care/Hospital Global News & Press Release Distribution

Health Care/Hospital

All
APAC

POMDOCTOR LIMITED to Participate in H.C. Wainwright's 28th Annual Global Investment Conference

Virtual company presentation will be available beginning September 11, 2026, at 7:00 a.m. ET GUANGZHOU, China, Sept. 10, 2026 /PRNewswire/ -- POMDOCTOR LIMITED ("Pomdoctor" or the "Company") (NASDAQ: POM), a digital healthcare company focused on advancing AI-enabled healthcare solutions, today a...

2026-09-10 20:00 1258

TenNor Therapeutics Reports Positive Phase IIa POC Data for Rifaquizinone (TNP-2092), the First Non-Surgical Therapy Candidate for Periprosthetic Joint Infection

— Phase IIb multicenter trial initiated, bringing this potential life-changing therapy closer to patients — SUZHOU, China, Sept. 10, 2026 /PRNewswire/ -- TenNor Therapeutics, a near-commercial-stage biotechnology company, today announced positive topline results from a Phase IIa proof-of-concept...

2026-09-10 19:30 1520

Full-Life Technologies Announces U.S. FDA IND Clearance and Australian Regulatory Clearance for [²²⁵Ac]Ac-FL-261 Phase 1 Clinical Trial

LONDON, Sept. 9, 2026 /PRNewswire/ -- Full-Life Technologies ("Full-Life", the "Company"), a privately held, fully integrated, clinical-stage actinium-based global radiopharmaceutical company, today announced that the U.S. Food and Drug Administration ("FDA") has cleared the Company's Investigati...

2026-09-09 20:25 1836

Transcenta Therapeutics and WuXi Biologics Enter into Strategic Collaboration to Accelerate Commercialization of HiCB Continuous Bioprocessing Technologies

PRINCETON, N.J. and SUZHOU, China, Sept. 9, 2026 /PRNewswire/ -- Transcenta Therapeutics (HKEX: 06628), a global clinical-stage biopharmaceutical company with fully integrated capabilities in discovery, R&D and process development of antibody-based therapeutics, today announced that it and its su...

2026-09-09 20:00 1533

Harbour BioMed Partner, Solstice Oncology, announces $225 Million Series A Financing to Advance Porustobart, a Neoadjuvant Immuno-Oncology Therapy

* Porustobart, a second-generation Fc-enhanced CTLA-4 antibody, is being advanced across two clinical indications in the neoadjuvant setting, beginning with MSS clinical stage II-III colon cancer * Phase 2 trial of porustobart for colon cancer will be open for enrollment early in the fourth q...

2026-09-09 19:12 1589

Health In Tech Named to Newsweek's America's Greatest Mid-Market Companies 2026

Health In Tech recognized among the 100 highest-scoring U.S. public mid-market companies following an initial review of approximately 4,300 companies, based on financial strength, workforce performance, innovation and sustainability STUART, Fla., Sept. 9, 2026 /PRNewswire/ -- Health In Tech, Inc....

2026-09-09 18:30 1218

HanchorBio Reaches Clinical Milestone for HCB101 as US FDA Allows Continued Treatment for Phase 1 Patient Experiencing Clinical Benefit

HCB101 represents the first known U.S. Expanded Access case for a SIRPα Fc fusion protein enabling continued therapy beyond the parent study. TAIPEI and SHANGHAI and SAN FRANCISCO, Sept. 9, 2026 /PRNewswire/ -- HanchorBio, Inc. (TWSE: 7827), a global clinical-stage biotechnology company developi...

2026-09-09 18:00 1297

Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Innovation

SHANGHAI, Sept. 8, 2026 /PRNewswire/ -- Natural Field, a technology-driven nutraceutical ingredient solutions provider, announced the expansion of its NF TriSolve® branded nutraceutical solution platform into the growing sleep wellness category with the introduction of NF TriSolve® SleepRestore ...

2026-09-08 22:00 2260

Natural Field Expands NF TriSolve® Platform Into Sleep Wellness With Science-Driven Nutraceutical Innovation

Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026

Three studies explore the relationship between tumor microenvironment, genomic alterations, and treatment response in non-small cell lung cancer using AI-based analysis SEOUL, South Korea, Sept. 8, 2026 /PRNewswire/ -- Lunit (KRX:328130), a leading provider of AI for cancer diagnostics and preci...

2026-09-08 21:00 1856

Lunit Unveils New AI-Powered Tumor Microenvironment Insights in Lung Cancer at WCLC 2026

GROWNSY Partners with Graham's Foundation During NICU Awareness Month to Support NICU Families Beyond the Hospital Stay

NEW YORK, Sept. 8, 2026 /PRNewswire/ -- GROWNSY, a baby care brand trusted by more than 3 million households worldwide, today announced a new long-term partnership with Graham's Foundation, a nonprofit organization dedicated to supporting parents of premature babies. The partnership will begin d...

2026-09-08 21:00 1424

GROWNSY Partners with Graham's Foundation During NICU Awareness Month to Support NICU Families Beyond the Hospital Stay

Accro Bioscience Announces IND Clearance from NMPA for Phase II/III Clinical Trial of AC-201, a Highly Selective TYK2/JAK1 Inhibitor for the Treatment of Non-Segmental Vitiligo

NEW YORK and SUZHOU, China, Sept. 8, 2026 /PRNewswire/ -- Accro Bioscience (Suzhou) Limited ("Accro") today announced that Shanghai Fosun Pharmaceutical Industrial Development Company Limited ("Fosun Pharma Industrial"), a subsidiary of its partner Shanghai Fosun Pharmaceutical (Group) Co., Ltd. ...

2026-09-08 20:20 1335

HBM9378/WIN378, an Ultra-Long-Acting Antibody Targeting TSLP, Achieves Positive Phase 2 Results in Asthma and Initiates Phase 3 Study

* The POLARIS-1 study enrolled 147 patients with uncontrolled, moderate-to-severe asthma, and the interim analysis was conducted on the first 98 patients. The analysis demonstrated a half-life of up to 75 days, with clinical effects consistent with twice-yearly dosing. * HBM9378/WIN378 produc...

2026-09-08 20:17 1469

Waterdrop Inc. Announces Second Quarter 2026 Unaudited Financial Results and a Cash Dividend

BEIJING, Sept. 8, 2026 /PRNewswire/ -- Waterdrop Inc. ("Waterdrop", the "Company" or "we") (NYSE: WDH), a leading technology platform dedicated to insurance and healthcare services with a positive social impact, today announced its unaudited financial results for the three and six months ended J...

2026-09-08 18:00 3388

/C O R R E C T I O N -- GCCL/

In the news release, "GCCL Strengthens Asia-Pacific Presence at Asia Bio Partnering Forum 2026," issued on September 8, 2026 by GCCL over PR Newswire, we are advised by the company that the name "Yoo-Hwa Choi" should read "Yuhwa Choi" throughout the release, as originally issued inadvertently. Co...

2026-09-08 16:05 1658

Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds

Following 100% transfusion independence in Chinese TDT patients, new study confirms tBE is equally safe and effective for African SCD patients and TDT patients from South/Southeast Asia. SHANGHAI, Sept. 7, 2026 /PRNewswire/ -- On September 7, 2026, Shanghai, Cell Stem Cell published online clini...

2026-09-08 08:00 1305

Cell Stem Cell: tBE-mediated Base Editing Therapy Achieves Durable Clinical Remission in Sickle Cell Disease and β-Thalassemia Across Different Genetic Backgrounds

U.S. District Court Invalidates Kaneka's Ubiquinol Patent, Clearing the Way for Cocrystal Tech's CrysQnol™ in the U.S. Market

Judge Overturns Kaneka's '080 Patent for Lack of Utility and Enablement, Removing Legal Uncertainty for Customers and Partners JIAXING, China, Sept. 7, 2026 /PRNewswire/ -- Cocrystal Technology (Jiaxing) Co., Ltd. ("Cocrystal Tech")today announced that the U.S. District Court for the Eastern Dis...

2026-09-07 20:30 3358

Ministry of Food and Drug Safety of Korea, Successfully Concludes 'GBC 2026,' Marking a Great Leap in Bio

– 5,600 participants from 19 countries discuss global bio innovation and the path forward – – Strengthened global regulatory cooperation, with a total of 23 meetings held with overseas regulators and industry, including 5 regulatory cooperation meetings – SEOUL, South Korea, Sept. 7, 2026 /PRNe...

2026-09-07 20:00 2688

Nature Biotechnology | Insilico's AI-Driven IPF Candidate Rentosertib Shows Potential for Biological Age Reversal, as Assessed by Six Proteomic Aging Clocks

* First-in-Class Evaluation of an AI-Driven Candidate: This is the first de-novo drug designed with generative AI for a de-novo target discovered using AI and Aging Research (AI aging clocks, AI models and Hallmarks of Aging Assessment). * First Universal Consensus Across Six Independently-De...

2026-09-07 17:42 1914

CelluPro Receives EXCiPACT™ Certification for GMP-grade Cell Culture Media Manufacturing, Strengthening Global Biomanufacturing Supply Capabilities

YANTAI, China, Sept. 7, 2026 /PRNewswire/ -- CelluPro, a biotechnology company specializing in serum-free cell culture media and bioprocess solutions, has achievedEXCiPACT™ GMP Certification for Pharmaceutical Auxiliary Materials (PAMs), becoming the first Chinese cell culture media supplier to r...

2026-09-07 14:00 1401

Prof Kevin Plaxco joins Nutromics as Chief Scientific Officer, bolstering expansion efforts for the DNA-based sensing platform

MELBOURNE, Australia, Sept. 7, 2026 /PRNewswire/ -- Nutromics, a Melbourne-based startup leading the frontier of DNA-based sensing, has announced the appointment of Professor Kevin W. Plaxco as Chief Scientific Officer (CSO). The company is preparing for the launch of its first product in 2027, ...

2026-09-07 13:14 1953

12 3 4 5 ... 321